In-house DEP trial prediction

I’m just going to go out in a limb and put this out there.

IMO, for anyone who believes our holy trinity of incompetents running Starpharma will successfully be able to partner any of our three in-house OPEN LABEL Phase 2 trialled drugs with a seriously good deal with a bonafide partner of significance this calendar year: Well I have a monorail to sell you.

P.S. The significance of the non-randomisation and open label trial is that after all these years AND at the end of this Phase 2, neither we, Starpharma or the investigators will know if the DEP drugs are more efficacious than than the original drug OR placebo.

This, sadly, IMHO, is the reality.

I’m only here for the next sugar hit.